Evidence map›Paper›PMID 23647969›Full record

ArticleMalaria journal2013

Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination.

Carlos J Chaccour, Kevin C Kobylinski, Quique Bassat, Teun Bousema, Chris Drakeley, Pedro Alonso, Brian D Foy

Registry-linked trialAbstract read
In one paragraph

Article in Malaria journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04407507 (Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects), which is not on this map. Cited by 97 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04407507 phase2completednot on this mapstarted 2020, after this paper: background citation

Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms

TypeinterventionalSponsorInvestigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.Ran2020 to 2021Enrolled66ConditionsCOVID-19ArmsIvermectin, Placebo
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. eLife · 2021
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Identification of the metabolites of ivermectin in humans.Pharmacology research & perspectives · 2021
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carlos J ChaccourInternal Medicine Department, Clínica Universidad de Navarra, Av, Pio XII 36, Pamplona 31008, Spain. cchaccour@unav.es
Kevin C Kobylinski
Quique Bassat
Teun Bousema
Chris Drakeley
Pedro Alonso
Brian D Foy

Funding

Ivermectin for Malaria ControlR01AI094349 · NIAID · COLORADO STATE UNIVERSITY · PI FOY, BRIAN DAVID · 2012 to 2015
$2.0M
NIAID NIH HHS 1R01AI094349-01A1NIAID NIH HHS R01 AI094349
6 · The paper itself

Abstract

backgroundThe heterogeneity of malaria transmission makes widespread elimination a difficult goal to achieve. Most of the current vector control measures insufficiently target outdoor transmission. Also, insecticide resistance threatens to diminish the efficacy of the most prevalent measures, indoor residual spray and insecticide treated nets. Innovative approaches are needed. The use of endectocides, such as ivermectin, could be an important new addition to the toolbox of anti-malarial measures. Ivermectin effectively targets outdoor transmission, has a novel mechanism of action that could circumvent resistance and might be distributed over the channels already in place for the control of onchocerciasis and lymphatic filariasis.

methodsThe previous works involving ivermectin and Anopheles vectors are reviewed and summarized. A review of ivermectin's safety profile is also provided. Finally three definitive clinical trials are described in detail and proposed as the evidence needed for implementation. Several smaller and specific supportive studies are also proposed.

conclusionsThe use of ivermectin solves many challenges identified for future vector control strategies. It is an effective and safe endectocide that was approved for human use more than 25 years ago. Recent studies suggest it might become an effective and complementary strategy in malaria elimination and eradication efforts; however, intensive research will be needed to make this a reality.

Indexed as

AnimalsAnophelesAntiparasitic AgentsClinical Trials as TopicHumansInsecticidesIvermectinMalariaMosquito ControlAntiparasitic AgentsInsecticidesIvermectin

Identifiers

PMID23647969
PMCPMC3658945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.